

# Accelerated Cure Project for MS

January  
2019



*Accelerating research towards a cure for multiple sclerosis*

## Repository Spotlight - Dr. Terrence Fisher, Vaccinex Inc.

Vaccinex, Inc. is a biotechnology company, based in Rochester, NY, working on the development of antibody-based therapies to treat neurodegenerative diseases. Semaphorin 4D (SEMA4D) is a protein expressed by immune cells that promotes immune activation and inhibits myelination. Suppression of this protein's activity would hypothetically promote remyelination. As part of their work to develop a SEMA4D antibody for both the diagnosis and treatment of MS, Dr. Fisher and his team analyzed 200 ACP Repository samples to see if SEMA4D levels are elevated during active disease. This work could provide important information regarding this protein's possible role as a biomarker in MS. Dr. Fisher's study is just one of more than one hundred studies using ACP Repository samples to advance and accelerate research into MS.

